HUMIRA 40 MG

Principio attivo:

ADALIMUMAB 40 MG / 0.8 ML

Commercializzato da:

ABBVIE BIOPHARMACEUTICALS LTD, ISRAEL

Codice ATC:

L04AA17

Forma farmaceutica:

SOLUTION FOR INJECTION

Composizione:

PEN

Via di somministrazione:

S.C

Prodotto da:

ABBVIE LTD, UK

Gruppo terapeutico:

ADALIMUMAB

Indicazioni terapeutiche:

* Rheumatoid arthritis: Humira in combination with methotrexate is indicated for: - the treatment of moderate to severe active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Humira has been shown to reduce the rate of progression of joint damage as measured by X-ray adn to impove physical function when given in combination with methotrexate. * Crohn's disease : Humira is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy.Humira is indicated for reducing signs and symptoms and inducing clinical r

Data dell'autorizzazione:

2009-07-01